Evidence map›Paper›PMID 34907706›Full record

ReviewJournal of applied biomedicine2020

The benefits of ascorbate to protect healthy cells in the prevention and treatment of oncological diseases.

Pavel Klener, Matthew Scott Alexander, Joseph John Cullen, Vera Stejskal, Jiri Sliva, Lucie Kotlarova, Pavel Kostiuk, Zdenek Prochazka, Marta Kucerova

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of applied biomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Pavel KlenerCharles University, Prague, Czech Republic.
Matthew Scott AlexanderDepartment of Surgery, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.
Joseph John CullenDepartment of Surgery, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.
Vera StejskalUniversity of Stockholm, Dept of Immunology, Wenner Gren Center, Stockholm, Sweden; Research Centre for Toxic Compounds in the Environment, Masaryk University, Brno, Czech Republic.
Jiri SlivaCharles University, Department of Pharmacology, 3rd Faculty of Medicine, Prague, Czech Republic.
Lucie KotlarovaInPharmClinic, Department of Pharmacology, Prague, Czech Republic.
Pavel KostiukEdukafarm, Department of Pharmacology, Prague, Czech Republic.
Zdenek ProchazkaEdukafarm, Department of Pharmacology, Prague, Czech Republic.
Marta KucerovaHospital Jablonec nad Nisou, Department of Oncology, Jablonec nad Nisou, Czech Republic.

Funding

NCI NIH HHS CA148062NCI NIH HHS CA184051
6 · The paper itself

Abstract

Health status is determined by the balance of oxidants and antioxidants which protects healthy cells against the threat of internal and external risk factors. Antioxidants such as ascorbate (vitamin C, ascorbic acid) are of fundamental importance in this respect. Ascorbate neutralizes potential damage caused by cellular oxidative stress which may be the greatest risk of damage to healthy tissue. Cellular oxidative stress is mediated by external factors (e.g. psychological stress, physical exertion, drugs, various diseases, environmental pollution, preservatives, smoking, and alcohol) and internal factors (products of cellular metabolism including reactive oxygen species). When the products of oxidative stress are not sufficiently neutralized, healthy cells are at risk for both mitochondrial and DNA damage. In the short term, cell function may deteriorate, while an increased production of proinflammatory cytokines over time may lead to the development of chronic inflammatory changes and diseases, including cancer. Although pharmaceutical research continues to bring effective chemotherapeutic agents to the market, a limiting factor is often the normal tissue and organ toxicity of these substances, which leads to oxidative stress on healthy tissue. There is increasing interest and imperative to protect healthy tissues from the negative effects of radio-chemotherapeutic treatment. The action of ascorbate against the development of oxidative stress may justify its use not only in the prevention of carcinogenesis, but as a part of supportive or complementary therapy during treatment. Ascorbate (particularly when administered parentally at high doses) may have antioxidant effects that work to protect healthy cells and improve patient tolerability to some toxic radio-chemotherapy regimens. Additionally, ascorbate has demonstrated an immunomodulatory effect by supporting mechanisms essential to anti-tumor immunity. Intravenous administration of gram doses of vitamin C produce high plasma levels immediately, but the levels drop rapidly. Following oral vitamin C administration, plasma levels increase slowly to relatively low values, and then gradually decay. With an oral liposomal formulation, significantly higher levels are attainable than with standard oral formulations. Therefore, oral administration of liposomal vitamin C appears to be an optimal adjunct to intravenous administration. In this review, the basic mechanisms and clinical benefits of ascorbate as an antioxidant that may be useful as complementary therapy to chemotherapeutic regimens will be discussed.

Indexed as

Ascorbic acidCancerComplementary therapyIntravenous vitamin CLiposomal vitamin COxidative stressVitamin C

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.